HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mineral Fusion Natural Brands launches

This article was originally published in The Rose Sheet

Executive Summary

Private equity firm North Castle Partners facilitates the union of Depth Bath & Body Care and cosmetics brand Mineral Fusion to create new natural cosmetics, hair-care and body-care competitor Mineral Fusion Natural Brands, according to a March 3 release. "The goal of Mineral Fusion Natural Brands is to provide superior natural personal-care products by being an industry leader in sales, innovation, quality, and value while carrying out the principles of sustainability. We intend to amplify the great work that has been done with Mineral Fusion and Depth, and delight a growing number of our consumers by accentuating the healthful benefits of both brands." says Thomas Brown, president of the new firm. North Castle portfolio company gloProfessional was involved in coordinating the venture, as well as industry veterans from Avalon Organics, which North Castle sold to Hain Celestial in 2007 (1"The Rose Sheet" Sept. 15, 2008, p. 10)

You may also be interested in...



North Castle Is Optimistic About Naturals, Discusses Ex-Brands Avalon, DDF

North Castle Partners is optimistic about the natural personal-care market despite some uncertainty as to how consumers faithful to such products in the past may react to the pressures of a lean economy, according to Lou Marinaccio, a managing director at the private equity firm

Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?

To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.

Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

UsernamePublicRestriction

Register

RS016008

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel